It was time for a change in neuroblastoma treatment planning, and this Original Report from the Journal of Clinical Oncology validates a revised classifier using the International Neuroblastoma Risk Group Staging System (INRGSS) while incorporating segmental chromosome aberrations (SCA) as an additional genomic biomarker.
In this comprehensive Journal of Clinical Oncology clinical review, the authors suggest that reexamination of breast cancer risk reduction strategies and clinical practice is needed. Prediction models, breast cancer mortality, prognostic categories, and the Women’s Health Initiative (WHI) randomized trials, dietary modification (DM) trial, hormone therapy trials, estrogen, and estrogen plus progestin trials are all […]
Getting out and enjoying the sunshine seems to be more important than ever right now, and some studies indicated that not getting enough of vitamin D may be a risk factor for all-cause mortality, and numerous researchers have concluded that we should all probably be getting a little more of it. According to the available […]
The findings, recently published in the Journal of Thoracic Oncology, suggested that patients with ALK rearrangements may benefit from prophylactic anticoagulation, and venous thromboembolism risk prediction scores may improve if ALK rearrangement status is incorporated.
After tobacco use and excess body weight, alcohol consumption is the third major modifiable cancer risk factor. In its latest guidelines, the American Cancer Society has tightened its grip on its recommendations, basically telling people not to drink alcohol at all if they want to prevent cancer risk.